Serotonin–GABA interactions modulate MDMA‐induced mesolimbic dopamine release
Open Access
- 27 October 2004
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 91 (4) , 852-859
Abstract
3,4,‐Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) acts at monoamine nerve terminals to alter the release and re‐uptake of dopamine and 5‐HT. The present study used microdialysis in awake rats to measure MDMA‐induced changes in extracellular GABA in the ventral tegmental area (VTA), simultaneous with measures of extracellular dopamine (DA) in the nucleus accumbens (NAC) shell. (+)‐MDMA (0, 2.5, 5 and 10 mg/kg, i.p.) increased GABA efflux in the VTA with a bell‐shaped dose–response. This increase was blocked by application of TTX through the VTA probe. MDMA (5 mg/kg) increased 5‐HT efflux in VTA by 1037% (p < 0.05). The local perfusion of the 5‐HT2B/2C antagonist SB 206553 into the VTA reduced VTA GABA efflux after MDMA from a maximum of 229% to a maximum of 126% of basal values (p < 0.05), while having no effect on basal extracellular GABA concentrations. DA concentrations measured simultaneously in the NAC shell were increased from a maximum of 486% to 1320% (p < 0.05). The selective DA releaser d‐amphetamine (AMPH) (4 mg/kg) also increased VTA GABA efflux (180%), did not alter 5‐HT and increased NAC DA (875%) (p < 0.05), but the perfusion of SB 206553 into the VTA failed to alter these effects. These results suggest that MDMA‐mediated increases in DA within the NAC shell are dampened by increases in VTA GABA subsequent to activation of 5‐HT2B/2C receptors in the VTA.Keywords
This publication has 47 references indexed in Scilit:
- Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus MonkeysNeuropsychopharmacology, 2004
- Effect of the acute and chronic administration of the selective 5‐HT6 receptor antagonist SB‐271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological studySynapse, 2004
- Pharmacological Studies of the Acute Effects of (+)-3,4-Methylenedioxymethamphetamine on Locomotor Activity, Role of 5-HT1B/1D and 5-HT2 ReceptorsNeuropsychopharmacology, 2002
- Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy VolunteersNeuropsychopharmacology, 1998
- MDMA induced dopamine release in vivo: role of endogenous serotoninJournal of Neural Transmission, 1997
- Effects of the Selective 5-HT2A Receptor Antagonist MDL 100,907 on MDMA-Induced Locomotor Stimulation in RatsNeuropsychopharmacology, 1996
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: OPPOSING ROLES FOR DOPAMINE AND SEROTONIN AT PRESYNAPTIC RECEPTORS IN THE VENTRAL TEGMENTAL AREAClinical and Experimental Pharmacology and Physiology, 1995
- Dopamine D1 receptors facilitate transmitter releaseNature, 1993
- Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by microdialysisLife Sciences, 1990
- Use of Calcium Antagonism for the Characterization of Drug‐Evoked Dopamine Release from the Brain of Conscious Rats Determined by MicrodialysisJournal of Neurochemistry, 1989